Basel Medical Group Ltd
BMGL
$2.02
-$0.17-7.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.03% | 3.97% | 4.84% | -- | -- |
| Total Other Revenue | -45.70% | -50.74% | -55.79% | -- | -- |
| Total Revenue | 2.80% | 3.72% | 4.56% | -- | -- |
| Cost of Revenue | 53.75% | 28.73% | 7.15% | -- | -- |
| Gross Profit | -44.24% | -23.93% | 1.12% | -- | -- |
| SG&A Expenses | -21.69% | -27.82% | -33.91% | -- | -- |
| Depreciation & Amortization | 23.47% | 9.34% | -3.73% | -- | -- |
| Other Operating Expenses | 361.13% | 180.14% | 52.86% | -- | -- |
| Total Operating Expenses | 56.85% | 28.57% | 3.84% | -- | -- |
| Operating Income | -109.86% | -64.87% | 7.33% | -- | -- |
| Income Before Tax | -95.84% | -54.63% | 13.01% | -- | -- |
| Income Tax Expenses | -128.88% | -96.10% | -5.86% | -- | -- |
| Earnings from Continuing Operations | -83.12% | -41.87% | 16.75% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.12% | -41.87% | 16.75% | -- | -- |
| EBIT | -109.86% | -64.87% | 7.33% | -- | -- |
| EBITDA | -108.68% | -64.03% | 7.24% | -- | -- |
| EPS Basic | -83.12% | -41.84% | 16.91% | -- | -- |
| Normalized Basic EPS | -95.87% | -54.63% | 13.04% | -- | -- |
| EPS Diluted | -83.12% | -41.84% | 16.91% | -- | -- |
| Normalized Diluted EPS | -95.87% | -54.63% | 13.04% | -- | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | -- | -- |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |